PETERSON SANDRA E 4

What Happened

• Sandra E. Peterson, a director of Seaport Therapeutics, was granted a derivative award covering 12,258 shares on April 30, 2026. The reported acquisition price is $0.00 per share (total reported value $0.00). The filing classifies this as an award/grant (derivative), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-30; Report filed with SEC: 2026-05-04.
• Reported price: $0.00 per share; Reported total value: $0.00.
• Shares owned following the transaction: not stated in the filing.
• Footnote: "The shares underlying this option shall vest in full on April 30, 2027, subject to the Reporting Person's continued service on such vesting date."
• Timeliness: Filing was submitted 4 days after the transaction date; Form 4s are generally required within 2 business days, so this appears later than the usual window.

Context

• This was a compensation-style derivative award (an option/award that vests in one year) rather than an immediate cash purchase or sale. The filing does not show an exercise, sale, or tax withholding related to the award; exercise/settlement mechanics beyond the vesting date are not specified.